Catalyst Pharmaceuticals (CPRX) Research & Development (2010 - 2026)

Catalyst Pharmaceuticals (CPRX) has 17 years of Research & Development data on file, last reported at $2.7 million in Q1 2026.

• Quarterly Research & Development fell 31.54% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.5 million (down 17.71% YoY) and the FY2025 annual result came in at $12.7 million, changed 0.48% from the prior year.
• Research & Development grew to $2.7 million in Q1 2026, from $1.8 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $83.7 million in Q3 2023 to a low of $1.8 million in Q4 2025.
• A 5-year average of $8.3 million and a median of $3.6 million in 2023 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2023 — Research & Development surged 906.76% — and 2024, when it tumbled 96.07%.
• Tracing CPRX's Research & Development over 5 years: stood at $4.1 million in 2022, then plunged by 51.82% to $2.0 million in 2023, then surged by 92.6% to $3.8 million in 2024, then tumbled by 52.42% to $1.8 million in 2025, then surged by 47.26% to $2.7 million in 2026.
• The last three Research & Development figures came in at $2.7 million (Q1 2026), $1.8 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.